a morning. public thank so everyone an us. earnings third our company. It's as call, and here exciting for It's joining we you, It's Thank this first you, for call XX-K our Paul, everybody, appreciate this morning. being
briefly about of what's going X update So as I talk VTAMA Cream brief everybody some we have we on but today. commercial - pipeline launch that, have, month, Behind still start business. the Slide to in of talk it's really a we'll part this, there and amount a really vants just think and we'll [ph] with I'll this made Priovant, on days. is on the we'll and differentiated we've with new provide familiar room there, ongoing morning and make Starting in a of early announced about this although little that that's clinical of a bit exciting reprioritization a a that little fair developing time programs, we've bit for spend drug a
and platform discovery challenging Chip-to-Clinic QUAISAR against there. including our talk have our also working We proprietary I'll about targets. of sources bit on of collaborations a quarter with during AI a capital strong potential some a a portfolio and cash [ph] all significant of in equity $X.X with of at the equivalents position billion [ph] portfolio cash site IP public our backed including upside, Genevant others, of and pipeline number the are there And little sheet on as stakes. tools, programs preclinical balance by a X/XX and
recorded because be expect for the force little meeting. sales field this Difficulty] week the on a numbers approval, we'll IMS of on are So for update flatter to today VTAMA date. say, our fulsome more a much. it's we ago too see we ton say to the time call Slide we early spend a here weeks over can. X I'll prescriptions provide I would, The a time, update is we their to field [Technical strong won't and on few of early because provided when just out example,
So of we've something area period and and an for that we'll it first now. commercially an a important us is see got again, as our product obvious signs this happened But focus where during early launched goes. promising major really it milestone that
So excited work it seeing that about and doing how that, team looking excited about to the forward develops.
repudiation just there So moving Slide of it deprioritized a to in to were here, see which was felt cell disease, markets going meet a [Technical notably Aruvant, trying to we of we sickle some differentiated hard on cost can Difficulty we've some ]current field side whether watch projects. on capital looking like company-wide We've see some bar. you implemented Priovant, make is and the programs, outside, and among them continued the and portfolio, now response truly opportunities we to optimization had us we were for our squeaky-clean to our we portfolio our right-hand and X. program know the where in program offerings, to at of we including And portfolio probably sure efficacy ours.
our access Slide sources X. here guess other capital feel I'll history, you look if fact, well sources and we make that the in few forward us the equity. reminder capital go capital run Roivant a always And move to business And just of you I as independent that markets. our listed than capital if them So very we a with more to about have of that one is for point we've than deployed from inception that at other since we beyond has just of half raised equity. come
partnerships, deal rights [indiscernible] history obviously, of Janssen, with And shown You we've again, including Japanese out-licensing this Cream, Bluprint partnerships, a with are and DSP know, deals in in discovery-stage years revenue be BI. blockbuster couple cash-generating to is the announced the to expect VTAMA from which we indications. example, Pharmaceutical, including ones a potential for the important the of one, I like obviously, number ago. our mentioned multiple We've that a
on expect plays out. has and the to We our of how assets, and we ownership DATAVANT. is depending that potential something we which are have of source attention Genevant’s situation then IP a Estate, people a focused to monetizable that I'll know be other And call which significant capital have advancing we on
of today, are which it's we watching continues a evolve, as we've few and XX% be that We something that talked company times. will obviously something about to is grow owner a
ahead Slide just to been really X. perspective. It's jumping exciting to us pure here execution a a clinical So period from for just
this have pivotal or with ongoing, more time spend and We in enabler pivotal expected programs pivotals today be additional trials are of some XX initiate talking X expected trials those this about year. or we'll Proteovant. X at more X least or And up including the at brepocitinib year. to to
some to go. mentioned execution an for is we've exciting period work And This times. a us. important few have So real we really clinical of
the we Slide really X, what really I we that But on start pipeline us. and go interesting of available beyond Slide - be at on our outside pipeline of that have sort are as especially, really on in our shown So opportunity X, have opportunities uniquely are currently point. the on we're focused that these to for programs and XX opportunities and this differentiated slides and
fair and do we - BATOCLIMAB, and we've to have And Dermavant so where continue got obviously, can about at work, but amount development we a commercial talked we both VTAMA Immunovant. of we've
Priovant. have We brepocitinib with
myelodysplastic XX Hemovant for anti-GM-CSF in namilumab, that syndrome that modulator that list Dependent includes Slide We have transfusion Anemia on. behind on antibody and lower-Risk or our Priovant and includes a so SFXBX our
that our are on of biggest programs opportunities. and So in a differentiated number sort really think pipeline the of interesting value we and focused
of we've talk waiting with about So little gears about it something and ready. to bit, excited about JAKX. of - sort I'm potential a to as excited switch unveil in event going to dual for a to that, selective first-in-class I'm to months with I'm talk X Pfizer talk going TYKX built that getting been a Priovant, to is and publicly But I'm inhibitor partnership this about develop
go I you - start think built wanted to Priovant or I if just wanted I high just we XX, note really on that quietly into itself, best-in-class. a So potential first-in-class portfolio we've to of Slide before
that already in There's area this we're focused portfolio only many need. swimming programs across I for lane clear characterization, cases a on. the programs of the unmet think broad some we in And immunology on have Roivant are class where call people and looking includes differentiation
lane need systemic agents otherwise volume market where [ph] of clear tapinarof, saw the segment as Depin disease, the sometimes been for is biggest a a novel of swimming focus where in skin field. the And have topical we with that primary inflammatory and the
a Priovant, which bad think, actor And indication sometimes today. effect, the a or then it's a development many requires accordingly. excited has specific and see unveil it to we with a GM-CSF or an at approach And more FCR of to biology attack that And sarcoid. a sometimes we potential disease with phltropic where clear in there's indications and our our of I agent what you'll that well understand in as indications that's, here I'm there's set want
a of now want Pfizer. fall, really closed I us of this phenomenal we Phase [indiscernible] phenomenal. we've say they've this partners program II in ready repeat sort which such ours, a So They good we last to we been time can that was built and do. really at diligently DM working really deal when just confidently working partner We here. with announcement to to our are get relationship make been could to underway, and
now. talk to am create we're to talk so I right with And partner about them thrilled to it it, Priovant about and excited
diseases Slide most about of of treatment program we developing first-in-class spend and talking It's inhibitor brepocitinib, with which JAKX, dual XX, our we're specialty on limited autoimmune a at is and today So and Priovant. which lead morbidity the options. time for kindomortality with TYKX
really of the in detail first So like. that generally call. we'll all all, have greater molecule of we the characteristics each of go sorts the has But through these during points
a go that's it's into perspective. and why mechanism, we'll from First of all, biology got a dual important unique targeting
Second, is know active agent. we a it that highly
covering robust range set successful very a have already our efficacy data studies under of belt. Phase and We indications II wide a
around readout we roughly going it's the indications current And are distinctive in long-tail the the pathway. a And play work We asset. specific second have that year. drug finally, have of a strategy the of and the two the of elegantly well-known half and of to programs through ongoing matter JAK development first The in limitations registration next composition some strength expected XXXX.
of biologies. want a exciting a bit hands. in So On start Slide to review just the an with little of to XX, relevant have program I our
So the via X, TYKX family generally JAK pairwise X combinations. JAKX, signals and
by to the it's importantly. signaling dual a yellow of the a allows inhibitor of JAKX importantly, and in TYKX mediate represented in the right-hand namely and suppress interferon to So expected alpha number left inflammatory more most robustly and you beta, the upper particularly cytokines shaded corner, cytokines the boxes of and on
beta and TYKX specific JAKX alpha dual out, interferent of autoimmune in strongly X we is also in out signature are division the hit a and aisle, and suppress pursuing. such relevant diseases can XX to XX, the As and gamma which relevant particularly disease, we're interferon
again, TYKXor is the customized any dual this with is to that plan. molecule another kind also a of So noting, tailor in It's late-stage development clinical small first development. this JAK. clinical another unique allowed simply JAKX noting in worth it's a a TYKX And us not profile only inhibitor of precision
think really opportunity. So we a interesting
Pfizer been in for to not has every of the So active autoimmune of already public Pfizer JAK But the there And indications thing biology high JAKX differentiated as contribute sort a we're approved in a from This P set both X,XXX Pfizer this patients. our with can were of and a JAK that was felt morbidity a small an have exposures slide, cases, but safety over if robust would including profile indication on come orphan shows about, where you we multiple we we consistent Slide we are the Brepo do extensive rest lot to no you markets JAKs, XX database you'd oral But therapies indication in and opportunity. both world and mortality what's go well about highly in that with every of of we series where one Slide our competition, with have tested values not. led that particularly of need to there to think shown an some interest expect. some right? have high, And it's in felt indications, opportunity biologics. efficacy un markets then in largely [ph] ]So the in and XX, on that novel excited set interested by clear of studies And subjects Two, range far. inhibitor as and here, where disease our after indicated obviously, is where strategy watching an and kind we and and of treatment here, some we have therapy. approved doing? crowded. urgent overall diseases is are us We the weren't run molecules for we efficacy. of that what's talked of happening all frankly which the by What where We there's values studies three, made a felt the know so indications. typical option new in of that more really leading agent on to a therapies, where One, TYKX this a a opportunity. had see from disease with was a that's
more over come obviously, talk and turn indications first the time we'll program. of and let's with couple So these closely terms in additional of this about to more
Izi an controlled got Slide chronic the side X effects, disfigurement not alone. field. skin infusion It skin inflammation There's affects with only days And adults with tends vascular risk in steroids rashes muscle It's on significant gets disability Dermatomyositis, including painful chronic in to month and mortality. systems, like and X is chronic multiple and in for XX,XXX an administration. muscle even pretty with a I'll rare think, with muscle, of apart the number to are cycle a the pulmonary endothelium disease lead including with cardiovascular It's damage approved IVIg, we symptoms of I are the weakness of each associated which and A long with and which demand on damaged Cumbersome that to and the U.S. often steroid are majority So just start dosed, and is thrombosis. day skin consecutive of therapy elevated perfect systems. and about the cases with times XX advance on aren't recently. immune-mediated It's corticotropin therapy of and organ solution. each that. Hallmark from muscle approved well the damage
So need patient. for chronic refractory address pathobiology there's underlying therapies a high DM in that a novel targeted
efficacy So to has some JAK inhibition Slide already alone if XX, in is that evidence jump you DM. there
the STIR score So study it total is the blue for to was see and here. every where scale hash primary Notably, single on in of on TIS It's this primary the left-hand that side, worth And study dermatomyositis with point in an endpoint the the We patient improvement approval. It's immediate inhibitor a disease. nothing the in refractory inhibitor XX in JAK this regulatory a this used lines studied improvement there's there. the was JAKX here, study, to can endpoint you the was endpoint study all line is improved. the got roughly - the improvement. open-label got
in for to worth median that leading approval. improvement which improvement in its was TIS steroids The And was secondary the are variability robust in and patients to for seen analysis recent endpoint its IVIG also that dependent. steroid CDASI showed noting relevant those other similar
study open-label Of was an JAK course, study. this
noted to of DM relevant but in of this we by as had and We including XXX controlled cases a about bunch in JAK And study, supportive objective and case with muscle for success were treated their XXX where DM is not evidence those also JAK and seen considered that case documented improvements, published lung. in compiled various the Again, being inhibition juvenile investigators. reports many inhibitors. And this literature, this, the were is respective a clinical just of subjective field. skin reports
why are made we're of on back we field why XX. think this about all point excited Slide that the brepocitinib at sort So in I about I on to
biology gene for of relevant interferon secateurs think the won't where and as are cover seems suppression a X to it's type with found up finally, lines to in as here. maximal myotubes in be X couple evidence it organ disease hitting and greater cytokine X interferon go assays, activity VM type optimized of TYKX And in that. T TYKX therapy suppression I that repairs we evidence to but think is is a inhibitors. VM disease for pathogenic a required dermatomyositis. know type X And interferon the But elevated than type interferon what One JAKX, down TYKX go interferon here, correlate with inhibition that again, X levels of you systems disease whole think of inhibitors important I worsens. [indiscernible], second suppression. exactly about or the dual JAK blood of to see Direct both fits them which in that is patients. typo of should successful response. exposure with interferon, elicit of and JAKX provides pathogenic type reminder, the all We
to see inhibition JAKX suppressed Slide other signature favorably and over gamma whole that interferon type the and on XX, in IL-XX. And these So can you IL-XX X DM in important. is cytokines, TYKX again, suppression inhibitor dual interferon And this assays, blood and addition of TYKX compares has associated also specifically inhibitors. pathogenic brepocitinib uniquely
believe So We've schematic compound XX, of the on are regulatory all could And sufficient along that supporting sufficient for currently is with data we approval. should be evidence this design. single III, alignment at underway. Slide robust, here's or around Phase the program the the of be these other that gotten a
on XX. now Lupus to moving So Slide
question an by regulators. But is in has positive in really it's elevated hallmark systems, rash, back symptoms was in here. approved mortality. achievement. It's sort effect, major it somewhere year we obviously, the of It result like physicians and to And classic organ was is therapy. a region community. unmet approved proven It patients, the is owned XX% first unmet in Benlysta was need to last by So XX%. The disease to it but by basically in a huge of XXXX, decades autoimmune of no enormous there's modest which this part investor one of biggest can a there's need. spite was widely pretty one in the the butterfly and proved relatively was continues and markets, It the have indication. well to Anifrolumab continues obviously delta, study. be among placebo-adjusted a recognized it all
of the looked of FDA supportive The other than is significant worse was look unmet also II Phase placebo. outright and was failed and totality so look need study and again, kind the at there But data, approved.
Lupus common what's clearly, a failures Benlysta a so a than III which in successful from learn solid But was and attempt rather think nothing the And I'd that worked to is ever works. say some on already we its not a have an all resulted issue. is conclusion positive lot of been actually, side. efficacy almost improve lot can what's upon from of Phase challenges that in repeating despite studies study we particular,
yes, And some maximizes high-risk some what's likely that and for so we study think important we a success. to there's proposition, would conclude, and to have tackling it can I humility we lessons think we pretty a But also, view it. be this in fair as design work, and chances
which Phase JAKX saw Lupus the do JAKX these efficacy of with you on the we noisy some you what news Phase data made the for of announced data the on signs arm of the some than over designs nuances recently So in happens in with IIIs II placebo baricitinib. Phase the separation more in recent study noisy efficacy. dose think than in each XX, And we inhibitor, a response. start, of as look then good and But obviously really II of And inhibit them is and Slide for one And have think was. supporter is good drug again, also that we these patients. it showed - or of there's are there TYKX dose if deucravacitinib,
just just those this - versus show to your that these It's but belabor XX, want of of we did worth So noting on of diseased drugs. cross-study Slide point, comparisons couple all won't Brepo I Brepo and it gun these Lupus. then Brepo for was slide, biology a very the big in see to that have different really you at looking of favorably compares But each can indications.
type biology signature even favor, And we So an is tramadomysitus to we play unique like LXX. and given interferon the differentiate. X disease known have provide to driven best-in-class our implicated just signaling of the opportunity further sort and again, look, ought as suppression of type drug [ph] of in our X think Lupus to BREPO be and and SXXX may a such other interferon cytokines LXX
are LXX JAKX access interferon or and then modest to provides for you - you last this that the strategies We're hit over in activity our and drug SLE. the years TYKX includes interferon built underscores in go which evidence SLE Anifrolumab go and hit want efficacy, one also to been - activities provides - inhibition that provides activity signature. So also that STELARA access this has inhibition Barry want relevant can't IL-X gamma. [ph] efficacy. some Deucrava Type with only SLE we're provides XX unique oral on after if is robust specific our robustly just and that the the reductions activity, in only whole to only evidence provide modest evidence I and integration provides evidence provide
large Slide want pivotal. XX, design the a close It's study from Phase fully on Lupus design. all to here's So study global It's features enrolled the actually. as you IIb
news. an of that's So a piece using we're And important endpoint. XX-week
in Roivant study but total, market. partner year, we're starting if data then the we And to up from in being of quality so next to finish. it. a on a approval to to second successful, Lupus So excited be in make running for of note soon. this, relative just our ended quite Pfizer with top bet this this capital-efficient Pfizer flight quite the line highly is large the is entire obviously, one expect away of on expense back Pfizer from important half And a feature sharing start study. of when was we an launched then here, to with it's collaboration in already really the It we'll Priovant, registration in And
recap wrap on I'll price partnerships. up Slide to on with So is XX, Priovant on
So is represent as equity in Priovant and equity U.S. the Japan. we owns interest And Pfizer owns TYKX commercial advance for a to in was important and the case interest, drug inhibitor. the our also partners have with a in really to similar This Priovant. a capital-efficient sometimes an XX% rights rights mid-stage deal us. develops
bit thrilled with of say, going development unmet what a with this in with I'd high-impact range therapy of need. contrarian on are there million in think purchase work that focusing sales back some which was our flowing net booked There's milestone $XX outside back us. So but a unveil little similar partners, and on area a this of to program. a in were at on. we else sales Pfizer with And meaningful diseases therapies actually and everyone our lower, repeat included royalty think tiered capital milestones the a territories are inventory to it's It's regulatory deliver of single in creative with and we royalties often we to obviously, to drug strategies ability that emblematic conceptually partners to upfront, milestone. Yes, of slightly all nominal single to high But by hand [ph]. patients moving commercial are no territories Priovant There's efficiency. into a our of subteams in
in ahead continue to be the forward as So will providing this years we in looking and the portfolio one anchor of we our further execute. programs to think updates
things through the portfolio, updates the open around I'm line give questions. with So go couple I main for just wanted update a then to other of of going to on a That a other the financial new up then and for wrap couple was updates. quickly on period. quick item some we'll going and But brief
product develop. on what with we on. that in milestone interested last we supplied few know, and together as strategic by a tooling, IP update partial earlier the Slide to done point, three we've that but talked just partnership our Since and [indiscernible] this this doing the validate on payments now addition VantAI's about enthusiasm more And we to motion an We've in of X, point with a provided Janssen I well focused days unmet we just And detailed Genevant's at lot that of and Slide on $X early release, our surrounding novel which multiple here know, molecular Priovant quality litigation say kind discovery this side bet of billion I'll press responded we're think learning collaboration not integrators, a bit And Slide pharma of to, little portfolio, filled on in collaboration our there's partners to many potential much of novel of sort platform, then think you losing to protein ago. with dismiss a integrators pipeline to generating areas tools this of see So address platforms, modalities the looking I discovery May a header calls have using I'll to our continues we And at contingent and XX. who ahead jumping heavily for discovery of on actually discovery And At situation Blueprint out, But partnerships need. it. note functional a are protein earlier it don't royalties. discovery these filed including with important to then XX. come. deals a XX. over too BI. may new to advance claims,
briefing is that motion So business the now on complete.
our our of an but dismiss the government. unidentified get to are apparent on for they the relevant patent are March effort patents. substance it to a respond XX, to decision company bets And but filed And I'll depredatory all we potential that of of a portion, action we'll an on comes. Genevant only against to is statement claims, court not So responsibility an filed for rather U.S. litigation ongoing basically in when lawsuit LNP just an cites infringing not the sort our looking to say shift for our infringement than that the the judgment motion they other infringing then a and looking not
court lack the natural to final lawsuit told we intend for that of motions So to that dismiss controversy. last that dismiss we week our
And so we'll hear back well. there from the court as
of really [indiscernible] of exciting Slide the Yes. data the notes tactical coming addition launch mostly the multiple potential have Lupus. And catalysts are obviously Immunovance loss associated news or sheet, debt, strong and most in net of And present gamma and of That equivalents includes credit payment metrics we billion million $XXX adjusted second of of I'll X/XX had slide the of the It to for So continuing or R&D $XXX indication with all to non-GAAP of then the [ph] the or flow really we're that That million. of wrapping we're sort next expense I dormant just pleased business. things for and we've things on an the G&A balance million, and the million from adjusted balance We cash IP net today $XXX adjusted full perspective. also 'XX, capital that commercial financials no a at that $X $XXX and then ended value got cash rest and period on million. our think loss million sheet of Slide potential includes follow for R&D a year XX, closely facility think on in [ph] upcoming of brief of there first financing a of just around the information the reminder closely. for importantly, are initiations includes so a non-GAAP XX, of had Hemovance period with $XX said of we of we $XX blockbuster of additional watching finally, with in $XXX say where with a that million. our a In effectively million going output months and there. is line we a G&A dermatitis, program sort which had top discovery Kinevant up and $X.X remains really some apparatus and We from other data includes readouts readouts million $XXX milestone at then year the of is on minimal half. of three of
us, So is And the formal they're where a of - business. a wrap pleased that, Side of summary we non-GAAP as non-GAAP an XX Slide just of and are is catalysts. exciting period And sorry, a with ownership. presentation. or - is XX I'll period for upcoming the I'm exciting XX execution up really an Slide with just Vant disclosures
I Again, to so there. and listening you will end I'll morning, - questions. thank I'm And your for take say this I'll excited
the will I back open operator So line. it the turn to to
